Related Experiment Video
Updated: Jul 8, 2026
07:35
Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
Published on: April 25, 2014
Rapid Detection of Resistance Mutations in Multidrug-Resistant Tuberculosis With GenoType MTBDRsl Assay
Shaina Gaikwad1, Antisha Tiwari1, Jitendra Singh2
1Department of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, aiims.edu.
Pulmonary Medicine
|July 7, 2026
Summary
The MTBDRsl V2.0 assay effectively detects fluoroquinolone (FQ) resistance in multidrug-resistant tuberculosis (MDR-TB) isolates, primarily through gyrA gene mutations. This tool aids rapid molecular resistance profiling in high TB-burden settings.
Area of Science:
- Microbiology
- Molecular Biology
- Public Health
Background:
- Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health threat.
- Resistance to fluoroquinolones (FQ) and second-line injectable drugs (SLID) complicates MDR-TB treatment.
- Rapid identification of resistance patterns is crucial for effective MDR-TB management.
Purpose of the Study:
- To evaluate the utility of the MTBDRsl V2.0 line probe assay (LPA) for detecting FQ and SLID resistance in MDR-TB isolates.
- To identify specific genetic mutations associated with FQ and SLID resistance.
- To assess the applicability of the MTBDRsl V2.0 assay in routine diagnostic settings.
Main Methods:
- Testing of 74 MDR-TB isolates using the GenoType MTBDRsl V2.0 LPA.
- Targeting resistance-associated mutations in gyrA and gyrB genes for FQ resistance.
- Targeting resistance-associated mutations in rrs and eis genes for SLID resistance.
Main Results:
- Fluoroquinolone (FQ) resistance was observed in 14 (18.9%) of the isolates.
- The majority of FQ resistance was associated with mutations in the gyrA gene, specifically A90V (6.7%) and D94G (5.4%).
- No mutations were detected in rrs, gyrB, or eis genes, and no resistance to SLIDs was found.
Conclusions:
- The MTBDRsl V2.0 assay is operationally useful for rapid detection of FQ resistance-associated mutations in MDR-TB.
- The assay's expanded mutation coverage and rapid turnaround time are beneficial for molecular resistance profiling.
- MTBDRsl V2.0 is a valuable tool for high TB-burden settings, aiding in timely treatment decisions.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...